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1. Introduction
Despite significant progress in the treatment of schizophrenia in recent decades, the evolution
of a large rate of patients suffering from this mental disorder is little influenced by treatment
[1]. The management of these patients, so-called treatment resistant, constitutes a public health
problem. Indeed, these very symptomatic patients often require long periods of hospitalization
[2], and their care consumes a disproportionately large share of total cost management of
schizophrenia [3].
Following the renewed interest in clozapine since 1988, thanks to the baseline study on the
neuroleptic Kane and al [4], and the development in this period of several explicit criteria
defining treatment-resistant schizophrenia (TRS), like those of Kane [4], Dencker and al [5] and
Brenner and al [6], some studies have subsequently estimated its prevalence.
The large number and variety of risk factors associated with poor prognosis or poor response
to treatment, reported in the literature, suggest that several pathophysiological mechanisms
may contribute to the emergence of resistance.
In this work, we tried to shed light on the prevalence of this concept, as well as its risk factors,
through a critical review of the literature.
2. Methodology
In our literature review, we conducted a literature search in two databases MEDLINE and
PUBMED. We used the following keywords: treatment-resistant, refractory, schizophrenia,
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prevalence, Correlates, predictors, poor outcome, Treatment refractoriness, Treatment
response, poor prognosis.
For studies estimating the prevalence of TRS, we selected the works that have considered the
resistance as a categorical diagnosis, defining it by explicit criteria.
For risk factors of TRS, we selected studies that have specifically studied the risk factors of
resistance, and the studies that studied the risk factors of poor prognosis or poor response to
treatment.
3. Prevalence of treatment-resistant schizophrenia
3.1. Results
The  prevalence  of  resistant  schizophrenia  ranged  from  5  to  60%  (Table  1)  in  the  four
studies  in  the  literature.  Vanelle  only found a  low rate  of  5% resistance because of  too
restrictive criteria of resistance corresponding to stages 5 and 6 of Dencker and May de‐
fining TRS.  The results  of  the  other  three  studies  suggest  that  an important  rate  of  pa‐
tients  do  not  derive  virtually  any  benefit  of  treatment  and  that  the  TRS  is  therefore  a
true public health problem [7]. Many authors agree on the fact that 1/5 to 1/3 of patients
are resistant to treatment [1].  Methodological  differences between these different studies
concerning  inclusion  criteria  and  the  TRS  criteria  were  important,  which  explains  the
wide variation in the estimate of the prevalence of TRS: 5 to 60%. The study by Juarez-
Reyes and al  [8]  illustrates this  fact.  Applying the criteria of  the FDA (Food and Drugs
Administration) for the prescription of Clozapine in the United States of America, Juarez-
Reyes et al found in their sample a prevalence of 42.9% of resistant patients,  but apply‐
ing the more restrictive criteria of Kane on the same sample, the prevalence dropped to
12.9%.
These methodological differences reflect a lack of consensus on the concept of TRS, which
seems to hamper research in this field, since the studies found were few, relatively old and
only conducted between 1990 and 1996.
3.2. Discussion of methodological differences
The methodological differences were related to:
3.2.1. Inclusion criteria
Essock [11] required in his sample only inpatients that must have had a total hospitalization
of at least 24 months for the preceding 5 years as inclusion criteria. It is clear that in such sample
the prevalence of TRS will be overestimated. By applying FDA criteria for eligibility to
Clozapine in this sample, Essock found the highest rate of TRS: 60%. Indeed, if outpatients
were including in the sample, prevalence of TRS would be less elevated. Essock [11] justified
such restrictive inclusion criteria by the fact "to ensure that Clozapine was most available for
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those most in need", because of the high cost of this treatment, and thus he recognized that he
did not screen TRS in all potentially patients in need to Clozapine, such as outpatients.
3.2.2. Criteria of TRS
3.2.2.1. Chronic hospitalization
In Vanelle’s study [10], which is based on the Dencker and May criteria [5] to define the TRS,
the need of continuous hospital stay was an essential criterion of resistance. Such highly
Authors Inclusion’s criteria Criteria of TRS Prevalence of
TRS
Number
of NLP trial
Minimal
duration of
NLP trial
Minimal dosage
of CPZ or its
equivalent
Assessment
scales
Terkelsen
(1990) [9]
Retrospective
estimates based on three
large-scale surveys, of
patients in New York
State
unspecified unspecified unspecified BPRS
CGI
.58 % of
inpatients and
24 % of
outpatients
Vanelle (.
5995) [10]
566 SKZ or SAD inpatients
since at least 6 months
disease duration since 3
years
2 3 months .5000 mg/a day CGI
level 5 and 6 of
May and
Dencker
classification of
treatment
response
5%
Juarez-
Reyes (.
5995) [8]
293 SKZ ou SAD 2 4 weeks 600 mg/a day BPRS
CGI
GAF
42.9 +/- 5.9%
Essock (.
5996) [11]
803 SKZ or SAD inpatients
since at least 4 months
and at least 24 months of
hospitalization during the
last 5 years
disease duration since 5
years
2 6 weeks .5000 mg/a day BPRS
CGI
FDA criteria for
eligibility to
Clozapine
60%
SKZ: schizophrenia; SAD: schizo-affective disorder; NLP: neuroleptic ; CPZ : Chlorpromazine; BPRS: Brief Psychiatric Rating
Scale; CGI: clinical global impressions; GAF: global assessment of functioning.
Table 1. Prevalence of TRS in the literature.
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restrictive criteria of resistance may underestimate TRS. This highly restrictive criterion seems
explaining the low rate of TRS in Vanelle’s study 5 % [10]. Currently, most authors agree that
chronic hospitalization is not necessary for criteria of TRS [1].
3.2.2.2. Duration criteria
Persistence of illness for more than 5 years was taken as the duration criteria for TRS by Kane
et al [4]. This was most probably the impact of serious side effects of clozapine (drug induced
agranulocytosis), which made researchers so stringent about duration criteria. Essock [11]
fixed this duration at 5 years and Vanelle [10] at 3 years. The other authors did not specify any
duration. Currently, most authors agree that waiting such durations are not necessary and a
clinical history of persistent psychosis for at least 2 years is sufficient for TRS [6,12]. Some
researchers have mentioned that even one year of unresponsiveness to treatment may be an
adequate time period [7].
3.2.2.3. Criteria of adequate drug trial
3.2.2.3.1. Duration of adequate drug trial
This duration ranged from 4 weeks to 3 months between the four studies (Table 1). Most
authors agree with the fact a period of 4 to 8 weeks is sufficient to evaluate the efficacy of a
therapeutic trial [13-17]. Conley [1] recommended in its definition of TRS established in 2001,
a period of 4 to 6 weeks, while the NICE (national institute for clinical excellence) recommends
a period of 6 to 8 weeks [18]. Nevertheless, some authors as Vannelle [10], Ciapparelli [19] and
Lindenmayer [20] consider that a period less than three months is insufficient to assess the
efficacy of a therapeutic trial.
This duration must vary according to symptoms taken into account when assessing the
therapeutic trial, because the different symptomatic dimensions do not evolve synchronously.
If the assessment of treatment response is based on the positive and negative symptoms, a
relatively short period seems sufficient. If the dimensions, such as social functioning, occupa‐
tional functioning, or quality of life, are included in the scope of the evaluation, a longer period
of evaluation should be required. However, the functional dimension of schizophrenia is less
specific to treatment response as positive or negative symptoms in a clinical trial, as it can be
influenced by several factors other than treatment [21,22].
3.2.2.3.2. Adequate dosage of neuroleptic
Despite the variation of this dose (600 to 1000 mg per day of chlorpromazine equivalents) across
studies, it was largely sufficient. Indeed, Kane set the minimum threshold dose, in its definition
of resistance, to 1000 mg per day of chlorpromazine equivalent [4]. But the results of more
recent studies, using the technique of positron emission tomography, showed that a dose of
400 mg of chlorpromazine daily can block 80-90% of dopamine D2 receptors in the nigrostriatal
pathway, and an occupancy rate of 60 to 80% of these receptors is sufficient to obtain a response
to neuroleptic treatment [23]. In addition It has been reported that higher doses produce no
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direct therapeutic benefit even in patients who are nonresponsive to therapy [24] and do not
improve efficacy in acute treatment [25].This dopamine antagonism is considered the main
mechanism of action of typical neuroleptics [23].Currently, most authors such as Barnes[13],
McEvedy [13], Dixon [26], Kinon [24], Shalev [27] and Conley [1] consider that doses between
400 and 600 mg per day of chlorpromazine equivalents are sufficient.
3.2.2.4. Adequate number of trials
Terkelsen [9] could not assess the adequacy of previous trials in his study because he con‐
structed retrospective estimation based on three large-scale surveys, conducted in 1987 and
1988, of patients in New York State. The remaining three authors (table 1) agree that the failure
of two trials is a criterion of treatment resistance, and not three as Kane had proposed in the
beginning in his initial definition of TRS. Indeed, the fact that there was only a 3% response
rate to prospective haloperidol treatment and a 4% response rate to double blind chlorpro‐
mazine treatment in the Multicenter Clozapine Trial led to the belief that failure of two
retrospective drug trials would be as effective as 3 in screening for treatment resistance [4].
Additionally, Kinon and al [24] mentioned that subjects who do not respond to 2 adequate
antipsychotic trials (1 retrospective and 1 prospective) have less than 7% chance of responding
to another trial. The FDA guidelines on clozapine use state that a patient before being treated
with clozapine should have failed to respond to two separate trials of antipsychotics. Several
guidelines such as APA (American Psychiatric Association) [28], NICE [18], IPAP (The
International Psychopharmacology Algorithm Project) [29], and TMAP (the Texas Medication
Algorithm Project) [30] also recommended that the number of trials of other antipsychotics
that should precede a clozapine trial is 2. Thus, two drug trial failures are now generally
accepted as the criterion for treatment resistance.
3.2.2.5. Scales for evaluating response to treatment
With the exception of the Vanelle’s study, all of the other studies have used the BPRS as the
main tool for assessing the clinical response (Table 1). In this scale the positive psychotic
symptoms are the most important. The response to neuroleptic treatment was considered
adequate if the score in the BPRS reduction ranges from 20 to 30% as suggested in the literature
data [31]. Cognition and subjective perspectives or other illness domains again have not been
incorporated into definitions of treatment response in TRS in these studies.
However, according to some authors, the definition of resistant schizophrenia must be
multidimensional, and the field to assess during a clinical trial should be extended and include,
besides the conventional positive and negative symptoms of schizophrenia, cognitive deficits,
quality of life, social reintegration, occupational impairments and behavioral problems [32-35].
But these positions are still controversial. This higher level of requirement is motivated by
improving in therapeutic arsenal in the field of schizophrenia as the widespread prescription
of Second Generation Antipsychotic (SGA), cognitive remediation and several types of
psychotherapy that are effective on certain dimensions of schizophrenia.
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3.2.2.6. The question of the type of antipsychotic
The four studies were consistent in the type of neuroleptic. During clinical trials of these
studies, only conventional neuroleptics (also called first generation antipsychotics: FGA) are
used. The results of these studies, therefore, reflect only the resistance of schizophrenia in this
type of neuroleptic. Recently, the evidence that second generation antipsychotics (SGA) are
somewhat more effective than traditional medications has opened the question of the type of
the drug patient should fail [36]. Currently, most authors [37] and guidelines such as APA
(American Psychiatric Association) [28], NICE [18], IPAP [29], TMAP (the Texas Medication
Algorithm Project) [30] and Clinical Practice Guidelines for the Treatment of Schizophrenia in
Adults of the Department of the COMMONWEALTH OF MASSACHUSETTS [38] agree that
failure to respond to second generation antipsychotics should precede a clozapine trial. In the
Schizophrenia Algorithm of the International Psychopharmacology Algorithm Project (IPAP)
[29] patient is regarded to be refractory if he or she failed to respond to monotherapy with Two
trials of Two Different SGA (or Two trials with a FGA, if SGAs are not available). Indeed,
atypical antipsychotics cause fewer early and late extrapyramidal neurological side effects,
improve adherence to treatment, would be more effective than conventional neuroleptics in
negative symptoms, cognitive deficits and mood symptoms, and may be effective in some
cases resistant to conventional neuroleptics, but without reaching the effectiveness of clozapine
for this indication [39].
3.2.2.7. Recommendations for future studies
Since 1996, the last date of study estimating the prevalence of TRS, there have been changes
in treatment practices in schizophrenia, such as the widespread prescription of atypical
antipsychotics, or more intensive deinstitutionalization of psychiatric cares in schizophrenia,
which could change the rate of resistance. There has also been a revision of the criteria of TRS
[1] as shown in the comparison of TRS criteria adopted by the four studies estimating the
prevalence of TRS to the recent data from the literature given above. New studies estimating
the prevalence of TRS and adopting the revised criteria of resistance seem to be necessary.
Pending the establishment of a broad consensus on the criteria of TRS, this will be precious
for research and therapeutic practice, the criteria of TRS that are currently almost unanimously
accepted in the literature are:
• A period of two years, during which the patient does not improve significantly, and has a
poor psychosocial functioning, seems reasonable even without long hospital stay.
• During this period, two well-conducted clinical trials have failed. The characteristics of an
adequate therapeutic trial would be:
• A period of 4 to 6 weeks each,
• A dose of 400 to 600 mg equivalent of chlorpromazine to classical neuroleptics
• Among the two trials that failed, one should include an atypical antipsychotic.
Even more restrictive criteria, such as Kane, should be reserved for experimental studies
evaluating the efficacy of new drugs in resistant schizophrenia.
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4. Risk factors of TRS
In this field, the literature is dominated by studies that have examined factors associated with
good or poor prognosis or outcome in general, or factors associated with good or poor response
to neuroleptic treatment in particular.
4.1. Risk factors related to the patient
The male gender is among the most documented risk factors of poor prognosis [40]. It was also
identified specifically as a factor associated with a poor response to neuroleptic treatment for
chronic patients and for patients seen during their first psychotic episode, by numerous studies
[41]. This male gender predominance in patients with TRS is explained by a greater sensitivity
of dopamine receptors to dopamine antagonism of neuroleptics in women, due to the antido‐
paminergic effect of natural estrogen [42].
The results of studies correlating the early age of onset and poor outcome are consistent [43,44].
This risk factor was associated with greater dysfunction in prospective studies [45], with poor
response to neuroleptics [46-48], with an increased risk of re hospitalization [49] and specifi‐
cally to the resistance [10]. Schizophrenia has a later onset in females than in males and the
difference has been found to be about 5 years in most studies [50] suggesting that the associ‐
ation between early age of onset and poor prognosis, is biased by the variable male gender.
However, the fact that the difference in age of onset between men and women disappears in
patients with TRS in many studies [44] argues for a direct influence, and independently of
gender, of age at onset on treatment response. The association between early age of onset and
poor outcome reflects a greater neurodevelopmental insult [51] that can be intensified by
environmental factors.
In terms of symptoms, severity of negative symptoms was associated with poor response to
treatment in many studies [35,52]. Other clinical aspects of schizophrenia were associated with
poor prognosis in the literature, as asociality [53] inappropriate or blunted affects [35,53], the
low level of premorbid functioning [54], a high degree of minor neurological signs [55], the
absence of affective symptoms [56,57], negative formal thought [52], excessive summertime
(July) and clustering of birthdates [58], morbid polydypsia [59], and a less severe overall basic
symptomatology (before starting treatment) [60].
In the psychological level, insight, poor coping, and some personality traits such as low social
skills, a lack of impulse control, and an intolerance of frustration, alogia would be factors of
poor response to psychosocial treatment [61-63].
4.2. Family and socio-environmental risk factors
The presence of family history of schizophrenia would be a poor prognostic factor [64]. A high
emotional expressiveness in the family environment was related to higher risk of relapses [65].
A history of obstetric complications is more common in patients not responding to neuroleptic
treatment [66]. The absence of precipitating factors [35] and a history of substance abuse
[67-70] were associated with poor response to treatment.
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4.3. Risk factors associated with cognitive deficits
Several literature reviews have summarized the evidence for associations between functional
outcome and cognitive deficits [71-73]. These reviews have regarded ranks of functional
outcome measures, including measures of skill acquisition in psychosocial rehabilitation
treatment, demonstration of ability to solve simulated interpersonal problems, and community
(social and occupational) functioning. The reviews indicated consistent and highly significant
relationships between ranks of key cognitive constructs such as episodic memory, immediate /
working memory, vigilance, and executive functions, and functional outcome in schizophre‐
nia. The effect sizes of these relationships tended to be in the medium to wide range.
According to several studies, the severity of cognitive deficits is equally or more important
than positive or negative symptoms to predict prognosis in schizophrenia [74].
4.4. Para clinical risk factors
4.4.1. The data of brain neuroimaging
The ventricular enlargement is the variable most studied in this field. Over the last three
decades, earlier computerized tomography and then MRI, cross sectional studies including
chronic patients have found an association between ventricular enlargement and poor
outcome [75-77]. Several longitudinal studies conducted during periods of 1 to 5 years of
chronic patients [78,79] or first psychotic episode patients [77,80] confirmed these structural
changes in the brain and found that they were progressive over the course of illness.
For the gray matter, reduction in total volume or located reduction in certain regions such as
the frontal, temporal and occipital cortex and ventral thalamus were identified [77]. In
addition, volumes of the putamen, especially dorsal and in the right hemisphere, showed
increases in patients with better outcomes, whereas putamen volumes in patients with poor
outcome did not differ from those in healthy comparison subjects [81]. Expansion of the
putamen is known to occur as a result of antipsychotic treatment, so that failure to expand in
patients with poor outcome may be related to their resistance to treatment [77].
Abnormalities of white matter located especially at the frontal and temporal lobe of the right
hemisphere were associated with poor outcome [77].
The results of longitudinal studies suggest that these brain volume changes seem to be
progressive, and occurred at an early stage of the illness [82].
Dynamic neuroimaging data found that lower pre-treatment striatal metabolism predicted
better clinical response to neuroleptic treatment and that drug responders showed a greater
increase in striatal metabolism after haloperidol therapy [83-85].
4.4.2. The biology data
In the literature, a smaller increase in plasma levels of prolactin [86,87], and a smaller decrease
in plasma homovanillic acid [88-91] following administration of neuroleptic, were associated
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with poor response treatment. A lower baseline plasma levels of homovanillic acid (before the
administration of a neuroleptic), was also associated with poor response to treatment [35,92].
A lack of clinical change after administration of amphetamine (central dopamine agonist) was
associated with decreased response to antipsychotics [93]. A blunted response of growth
hormone after stimulation with apomorphine [94] has been associated with poor prognosis.
All  these  factors  reflect  a  poorer  response  to  central  dopaminergic  action  of  dopamine
antagonist antipsychotics. The hyperactivity of central dopaminergic mesolimbic pathway
remains the predominant mechanism that explains the positive symptoms of schizophre‐
nia [39].
4.4.3. The data of electrophysiology
The MMN (mismatch negativity) is an early component of auditory evoked potential, recorded
after a disruptive auditory stimulus. The peak of MMN occurs after 100 to 150 milliseconds
after the stimulus. Abnormally increased MMN amplitude, as well as abnormal MMN
topographical distribution, was associated with a poor functional outcome in schizophrenia
[95]. These anomalies reflect pre-attentive deficit process (or automatic attention), related to
neuropathological changes in the auditory cortex in schizophrenia [95].
4.4.4. The Electrodermal Activity (EDA)
Some studies have found that heightened electrodermal activity, as indicated by frequent
orienting responses to innocuous stimuli, elevated skin conductance level (SCL) and frequent
nonspecific skin conductance responses (NS-SCR), is associated with most often poor symp‐
tomatic, social and occupational outcome in schizophrenic patients [96].
4.5. Risk factors associated with treatment
The initial duration of untreated psychosis, namely the time gap between the onset of psychotic
symptoms and first treatment, also called DUP, is among the most studied risk factors for poor
outcome during the last 2 decades [97]. Evidence from both retrospective and prospective
studies suggests that a longer duration of untreated psychosis in the early stage of schizo‐
phrenia is associated with a longer time to remission and a lower level of recovery, a greater
likelihood of relapse and a worse overall outcome [98]. Perkins in a recent meta-analysis has
retained a total of 43 publications from 28 sites. He found that shorter DUP was associated
with greater response to antipsychotic treatment, as measured by severity of global psycho‐
pathology, positive symptoms, negative symptoms, and functional outcomes [97].These
findings are frequently interpreted as a consequence of a more intense and rapid progression
of a neurodegenerative process in the first years of untreated illness [99].
Response to treatment,  at  least  in some cases,  appears to decrease over psychotic  relap‐
ses. As a result patients have lower rates of remission and longer duration to achieve it
[100].  Lieberman and colleagues [101]  measured time to remission over three successive
psychotic  episodes  and  found  that  the  time  to  reach  remission  more  than  tripled  be‐
tween the first and third episode.
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Moreover, the absence of a significant and rapid reduction of symptoms during the first days
of neuroleptic treatment (3 to 7 days) [60], the dysphoric subjective response type at an initial
dose of neuroleptic [60], a bad alliance with the therapist [63], the occurrence of neurological
side effects such as parkinsonism [102], akathisia [10] or tardive dyskinesia [102], predict a
poor response to treatment.
4.6. Methodological considerations
In our literature review we have considered the factors influencing the prognosis and response
to treatment as factors that may explain the resistance. This choice can be criticized. On the
one hand, a poor prognosis or a poor response to neuroleptic treatment is not synonymous
with therapeutic resistance. On the other hand, the prognosis is a broader concept that the
response to treatment and thus the factors influencing prognosis and those influencing
treatment response can be inter-related but not necessarily identical [60]. Accordingly, it is
important to consider these potential factors of resistance with caution.
Tools for evaluating the response to treatment or prognosis varied widely, limiting their
comparability. Consensus specifying tools for assessing treatment response and prognosis in
schizophrenia is therefore of great interest for research in this field [60]. The criteria for
remission in schizophrenia proposed by Andreasen et al [103] can be a great help for future
studies [104].
In  this  area of  research,  the  results  of  longitudinal  studies  examining schizophrenic  pa‐
tients  prospectively  from  their  first  psychotic  episode  are  more  reliable  than  cross-sec‐
tional  studies  retrospectively  examining  chronic  patients  [102].  Indeed,  in  samples  of
chronic  patients  examined retrospectively,  there  is  firstly  an  overrepresentation  of  poor
responders or patients with less favorable prognosis, and secondly, a greater heterogenei‐
ty because these chronic patients are at different stages of the disease and were exposed
for varying periods at different neuroleptics. While in samples of patients followed from
their  first  psychotic  episode  in  longitudinal  studies,  there  is  a  greater  representation  of
the  broad  spectrum  of  response  to  treatment  or  prognosis,  and  a  greater  homogeneity
because  patients  are  at  the  same stages  of  the  disease  (the  first  months  or  years  of  ill‐
ness) and the exposure to neuroleptics was controlled [102].
Some risk factors of TRS are known to be interrelated, like poor premorbid sociosexual
functioning [77] and cognitive deficits that are related to severity of the negative symptoms.
At end of design studies with methodological rigor use of statistical techniques such as
multiple regression and the development of more complex predictive models is needed for
future studies in this area.
4.7. The pathophysiology of TRS
The pathophysiology of TRS is still unclear. Some risk factors for TRS cited above as the low
level of premorbid adjustment, male gender, severity of primary negative symptoms, the
greater frequency of obstetric complications, the high degree of minor neurological signs, and
the vulnerability to develop tardive dyskinesia, suggest a neurodevelopmental origin [98].
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These neurodevelopmental factors are more frequently found in patients resistant to treatment
from the first clinical trial. Moreover, these factors may have an additive effect, i.e. there should
be coexistence of a critical number of such factors for there to be resistance [98]. According to
some authors [59,105,106] these factors are the characteristics of a more severe subtype of
schizophrenia (Kraepelinian schizophrenia) less influenced by neuroleptic treatment.
However, some patients worsen over the course of their illness either because of its progression
or because they become less responsive to treatment [101]. Other TRS risk factors mentioned
above as DUP, progressive changes in brain volumes in early stage of illness and the deterio‐
ration of treatment response over relapses, support the hypothesis that the resistance would
be secondary to a neurodegenerative process, which alters the response to treatment in a
progressive manner, and not to a static and finished neurodevelopmental process [99].
Candidate’s neurons for the seat of this neurodegeneration include dopaminergic projections
to the cortex, and glutamatergic cortico-cortical projections. This neurodegeneration is due to
excessive glutamatergic excitation (excitotoxicity) triggered by the disease, involving the
NMDA subtype of glutamate receptor that is coupled to an ion channel for calcium. This
excessive excitation induces an excess of intracellular calcium, which activates certain intra‐
cellular enzymes which dangerously begin to produce free radicals that destroy the cell [39].
For other authors, these two hypotheses, neurodevelopmental and neurodegenerative, are not
mutually exclusive, but in fact they are complementary [98]. Each comes at different stages of
the disease in the genesis of resistance to treatment. However, the neurodegenerative hypoth‐
esis is more optimistic, because it suggests that treatment resistance is not inevitable, it does
not follow the law of all or nothing, at least for some patients, and it would be possible to
protect patients against the development of resistance to treatment by receiving early effective
and continuous treatment.
4.8. The perspectives
Some risk factors for TRS cited in this literature review, are promising and interesting, and
require a particular interest in future studies because they offer an more positive and optimistic
approach of the concept of TRS.
4.8.1. The initial duration of untreated psychosis
It is a potentially modifiable risk factor, offering hope for effective therapeutic intervention to
avoid resistance by shortening this duration. Indeed, some preliminary studies have found
that shortening this period is possible by means of early detection programs [107], and that
early intervention can favorably influence the prognosis of schizophrenia [108,109]. Addition‐
ally, evidence for a neuroprotective effect of some forms of early treatment such as atypical
antipsychotics is beginning to emerge. Atypical antipsychotics may counteract some of the
progressive deteriorative effects by enhancing synaptic plasticity and cellular resilience [99].
Finally, understanding the mechanism by which duration of untreated psychosis influences
prognosis may lead to better understanding of the pathophysiology of schizophrenia and to
improved current treatment strategies [97].
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4.8.2. Cognitive deficits
Cognitive impairment has emerged as an important new target in schizophrenia therapeutics
in light of evidence that cognitive deficits are critically related to the functional of disability
that is characteristic of the illness. The cognitive impairment is a risk factor for TRS that is
potentially accessible to efficient therapeutic interventions. Indeed, in addition to atypical
antipsychotics that are more effective in improving cognitive deficits than classical antipsy‐
chotics [39], there is now enough evidence that some rehabilitation therapies such as cognitive
remediation - a cognitive computerized training - can change and improve these deficits [110],
and thus it is another promising way forward.
4.8.3. Some paraclinical tests
The mismatch negativity (MMN) is an electrophysiological recording that could predict poor
outcome in patients with schizophrenia. It has the advantage of being harmless, quick and
easy to made, with low cost, and can be coupled with functional neuroimaging (fMRI) to
increase its spatial resolution [95,111]. Like the mismatch negativity, research can provide
"biomarkers" associated with prognosis or response to treatment. Predicting precociously a
poor outcome using such convenient test will give the therapist the opportunity to optimize
treatment at the first trial.
4.8.4. The glutamate hypothesis for schizophrenia
The promising findings of researches on the glutamate hypothesis in pathophysiology and
treatment of schizophrenia allow hope for having future drugs modulating glutamatergic
neurotransmission (such as NMDA-receptor agonists) that seem to be promising in difficult-
to-improve symptoms as cognitive impairments and negative symptoms [112,113]
4.8.5. The need for future studies
Setrn and al found in there review of the literature about predictors of response to neuroleptic
treatment in schizophrenia, that predictive models explained less then 80 % and more
frequently less than 40 % of the outcome variance. These findings suggest that there are other
factors influencing the prognosis of schizophrenia, which are still unknown [60], hence there
is an important need for further studies in this area.
5. Conclusion
TRS remains a challenge for clinical practice and research. It is an undeniable and frequent
clinic reality and a real public health problem. For research, having a wide consensus defining
the boundaries of TRS is important for comparability and reliability of future studies. TRS is
a heterogeneous entity, and has a multifactorial determinism. It is not, at least for some
patients, a fatality, but rather the culmination of several risk factors, some of which seem to be
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accessible to effective therapeutic interventions. According to this opinion, TRS would be
partly preventable and reversible.
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TRS : treatment-resistant schizophrenia;
SKZ: schizophrenia;
SAD: schizo-affective disorder;
NLP: neuroleptic;
CPZ: Chlorpromazine;
BPRS: Brief Psychiatric Rating Scale;
CGI: Clinical global impressions;
GAF: Global assessment of functioning;
SGA: Second generation antipsychotics;
FGA: first generation antipsychotics;
APA: American Psychiatric Association;
NICE: National institute for clinical excellence;
IPAP: The International Psychopharmacology Algorithm Project;
TMAP: The Texas Medication Algorithm Project
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